NCT00807196 - Zevalin With Non Myeloablative Allogeneic Stem Cell Transplantation in Patients With Non Hodgkin Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2008

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2012

Conditions

Non-Hodgkins Lymphoma

Interventions

DRUG

Rituximab

250mg/m2 day -21 and day -14 of preparative regimen

DRUG

90Y ibritumomab tiuxetan (Zevalin)

0.4 mCi/kg IV on day -14 of preparative regimen

DRUG

Cyclophosphamide

300mg/m2 IV daily for 5 days day -8 to day -4 of preparative regimen

DRUG

Fludarabine

30mg/m2 IV daily for 5 days day -8 to day -4 of preparative regimen

OTHER

Non myeloablative allogeneic stem cell transplantation

Blood stem cell infusion on day 0

Trial Locations (1)

RECRUITING

Hopital Maisonneuve-Rosemont, Montreal